nTranexamic

Tranexamic acid has functional skin lightening activity in the treatment of melasma, as it can inhibit melanin synthesis by blocking the plasminogen/plasmin pathway, thereby preventing the interaction between melanocytes and keratinocytes. Additionally, it can promote skin exfoliation, leading to the regeneration of epidermal and dermal tissues and the reduction of pigmentary discolorations. Tranexamic has an average size of 200 nm, allowing for a more gradual and prolonged release of the encapsulated active ingredient, reducing skin irritability.